What is the mechanism of action of Jisanda/Bingtonsa as a targeted drug?

Epclusa is the core oral targeted drug for modern hepatitis C treatment. Its mechanism of action profoundly reflects the current direction of precision and molecular targeting of antiviral treatment. Epclusa is a combination of two direct antiviral drugs (DAAs), namely the NS5B polymerase inhibitor Sofosbuvir and the NS5A inhibitor Velpatasvir. The two synergistically block multiple stages of viral replication and assembly, significantly improving the virus clearance rate and reducing the risk of drug resistance.

First of all, sofosbuvir is a nucleoside analog whose target isNS5B RNA-dependent polymerase of HCV virus, which is a crucial enzyme in the replication process of hepatitis C virus. After sofosbuvir is metabolized into the active triphosphate form in the body, it can be competitively incorporated into the viral RNA chain, causing chain termination, thereby interrupting the viral RNA synthesis process. Due to its highly conserved target properties, HCV of different genotypes are sensitive to sofosbuvir, making it one of the foundations of a pan-genotypic treatment program.

Secondly, velpatasvir is an NS5A inhibitor. It blocks the formation of viral RNA replication complexes and inhibits the assembly and release of viral particles by interfering with the function of NS5A protein. NS5A protein is involved in multiple aspects of the virus life cycle, and its inhibition can quickly exert its inhibitory effect before the virus replicates in large quantities. It has the characteristics of fast onset and wide expansion. When used in conjunction with the NS5B target, it can enhance the overall antiviral effect and reduce the probability of virus escape and drug resistance.

This kind of "multi-target, dual-mechanism" combination design is the core scientific basis of Jisandai's efficient treatment of hepatitis C. Unlike traditional treatments that rely on immune enhancers such as interferon, Epclusa can directly intervene in key stages of the virus life cycle to quickly reduce viral load and achieve virological clearance. More importantly, this mechanism of action makes it widely applicable to patients with all HCV genotypes, including those who have failed previous treatment and those with HIV co-infection.

Reference: https://www.epclusa.com/